HDAC9 and chronic myelogenous leukemia, BCR-ABL1 positive: Treatment with HDAC inhibitors (HDACi) effectively targets the quiescent chronic myelogenous leukemia (CML) stem cells which are resistant to tyrosine kinase inhibitor imatinib mesylate (IM) [145].